Lexington, MA, United States of America

Qingyi Yang

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 8.3

ph-index = 1


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: **Qingyi Yang: Innovating in Melanocortin Receptor Research**

Introduction

Qingyi Yang is a notable inventor based in Lexington, Massachusetts, known for his significant contributions to the field of pharmacology. With an impressive portfolio of seven patents, Yang's innovations focus on treatments associated with melanocortin 4 receptor-related conditions.

Latest Patents

Qingyi Yang's latest patents showcase cutting-edge methods for antagonizing the melanocortin 4 receptor (MC4R). These include detailed descriptions of methods for treating MC4R-related conditions using compounds of a specific formula. Additionally, he has outlined the pharmaceutical compositions that contain these compounds and their salts, aimed at treating conditions like cachexia, anorexia, or anorexia nervosa. Yang's patents are essential for understanding the potential therapeutic applications related to these compounds.

Career Highlights

Yang's professional journey has largely been associated with Pfizer Corporation, where he utilizes his expertise to drive innovative research. His work stands at the intersection of biology and pharmacology, focusing on regulatory mechanisms involving the melanocortin system and its implications for various health disorders.

Collaborations

He collaborates closely with notable colleagues Matthew Forrest Sammons and Dafydd Rhys Owen, contributing to multidisciplinary efforts in addressing healthcare challenges through pharmaceutical innovations. These partnerships enhance the quality and breadth of Yang's research, fostering an environment of shared knowledge and creativity.

Conclusion

Qingyi Yang's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents not only reflect his dedication to advancing treatment methodologies for severe health conditions but also represent a significant leap in our understanding of melanocortin receptors. As he continues his work at Pfizer Corporation, his future contributions are eagerly anticipated within the scientific and medical communities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…